<DOC>
	<DOCNO>NCT00256542</DOCNO>
	<brief_summary>The purpose study determine whether intravesical U101 ( alkalinize lidocaine-heparin ) treatment reduces symptoms pelvic pain and/or urgency bladder origin .</brief_summary>
	<brief_title>Study U101 Bladder Pain and/or Urgency</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Male female subject least 18 year age . Subjects must give write informed consent participate trial . All female subject , except postmenopausal and/or surgically sterilize , must consent use two medically acceptable method contraception throughout entire study period . Medically acceptable method contraception may use subject and/or partner include : abstinence , birth control pill , diaphragm spermicide , intrauterine device ( IUD ) , condom foam , vaginal spermicidal suppository , progestin implant , DepoProvera injection . Subjects must symptoms pelvic pain and/or urgency . Medical history physical examination result must clinically acceptable Investigator . Medical Monitor may evaluate subject â€™ meet eligibility criterion . Female subject currently use hormone therapy ( HT ) must use HT least 3 month . Subjects le 18 year age . Subjects know hypersensitivity heparin lidocaine . Female subject positive pregnancy test time screening , pregnant lactating , plan become pregnant study period . Subjects chronic user narcotic use narcotic time study entry . Subjects hepatic disease clinically significant abnormal liver function test ( twice upper limit normal range ) . Subjects expect available entire duration study . Subjects coexist significant medical condition likely interfere study procedure ( cardiovascular , hematological , central nervous system , pulmonary , renal , etc . ) Subjects treat dimethyl sulfoxide ( DMSO ) bladder instillation therapy within three month prior study entry . Subjects cystoscopic dilatation bladder urethra within three month study entry . Subjects take used investigational drug device within 30 day start study , currently enrol another investigational study . Subjects contemplate schedule invasive surgical procedure study period . Subjects unwilling unable abide requirement study . History gastrointestinal ( GI ) bleed Active bleeding source Screening activate partial thromboplastin time ( aPTT ) normal limit Systolic blood pressure ( BP ) &gt; 180 mmHg &lt; 90 mmHg Screening . Subjects actively bleed lesion/area bladder detect urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>interstitial cystitis</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>urgency</keyword>
	<keyword>frequency</keyword>
	<keyword>Pelvic Pain and/or Urgency Bladder Origin</keyword>
</DOC>